In an attempt to simulate what happens in the body when type 2 diabetes develops and to better study how the body reacts to drug treatment, researchers at Lund University in Sweden have developed a new mouse model that confirms how the disease progresses.
Insulet, creator of the OmniPod tubeless insulin pump, joined forces with Eli Lilly this week to develop a new version of the device designed to deliver Lilly's Humulin R U-500 insulin.
Investigators at the Harvard Stem Cell Institute have discovered a hormone with the ability to produce beta cells--the insulin-producing cells found in the pancreas that are lost in diabetes--that could potentially treat type 2 diabetes more effectively.
It might not be the Fountain of Youth, but U.K. scientists have found that a common diabetes drug appears to extend the lifespan of common worms.
Intarcia Therapeutics enrolled its first patients in Phase III trials for its Type 2 diabetes treatment to be delivered underneath the skin.
Novo Nordisk completed a Phase I trial of its oral insulin drug, adding Novo to a short list of companies in the running to have the first version of the diabetes pill on the U.S. market.
The FDA is taking a closer look at the increased risk of Type 2 diabetics getting pancreatic cancer from the popular drugs like Merck's blockbuster Januvia and Byetta from Bristol-Myers Squibb.
GI Dynamics is planning for a big entry into the massive Brazilian market with its non-surgical device to treat type 2 diabetes and obesity. And it will use a local distributor to accomplish this: Brazil's CMS Medical.
GI Dynamics has kicked off its large-scale trial of the diabetes-treating EndoBarrier, and CEO Stuart Randle said the company is on track to file with the FDA in 2015
A new glimpse into the workings of the anti-diabetic drug metformin showing that its mechanism of action isn't quite what people have thought could lead to new drugs for the growing need in Type 2 diabetes.